Life Sciences

We act for clients in a wide variety of life science transactions, ranging from strategic licensing transactions and development and supply agreements, to biologic material transfers and technology transfers from research institutions, research agreements with large teaching hospitals, and contract research organization agreements. Our clients include medical device and biotechnology start-ups, international “big pharma” companies and technology transfer arms of research institutions. Our firm also advises on regulatory matters relating to the healthcare field.

Representative experience:

• Supply and distribution agreements between Omrix Biopharmaceuticals and local distributors in Europe, the Middle east and the Far East.
• Representation of a major multinational pharmaceutical company in the spin-off and out-licensing of a portfolio of pharmaceutical products for gastro-intestinal indications.
• Sourcing agreement between Regentis Biomaterials and Baxter Healthcare Corporation for the purchase of biological material for use in clinical trials.
• Co-marketing agreements for biomarkers between Glycominds and European pharmaceutical companies.
• Clinical validation agreement between Glycominds and multinational European-based pharmaceutical company.
• Licensing and distribution agreement between Notal Vision and Carl Zeiss.
• Patent license agreement with Brigham and Women’s Hospital for specialty pharmaceutical company on a Phase III combination drug.
• Patent purchase agreement between Kyoto University and Israeli biotech company on pre-clinical chemokine-based drug.
• License, purchase and sponsored research agreements between biotech start-ups and the technology transfer arms of research institutes, such as University of Texas (MD Anderson), MIT, Stanford, the Weizmann Institute (Yeda), Hebrew University (Yissum), Technion, Tel Aviv University (Ramot), Hadassah (Hadasit) and Brigham and Women’s Hospital.